Global Pandemic Preparedness Summit 2024 Outcomes Report—now available!

Global Pandemic Preparedness Summit 2024 Outcomes Report—now available!

The Global Pandemic Preparedness Summit 2024: Outcomes Report, now available to read and share, captures the discussions and recommendations that emerged from the Summit.

The report distils the key outcomes, reflections, and recommendations shared by over 80 expert speakers during the two-day event co-hosted by Brazil’s Ministry of Health, Fiocruz, and CEPI in Rio de Janeiro, Brazil, on July 29 and 30, 2024. The Summit programme focussed on three central themes: enhancing global disease surveillance, delivering the 100 Days Mission for vaccines, diagnostics and therapeutics, and enabling equitable access to these interventions through geographical diversification and strengthening of R&D and local and regional production. While progress has been made in some of these areas since the COVID-19 pandemic, the report highlights that the world is not yet ready to tackle the next pandemic threat.?

Summit discussions highlighted growing consensus around the most significant gaps and weaknesses in pandemic preparedness and response and how to overcome them. These included broad scientific consensus around the pathogen family approach to R&D, growing cross-sectoral support for the 100 Days Mission, and acknowledgement of the need for strong regional collaboration to enhance surveillance, R&D, and manufacturing capacity in the Global South.

Heightened focus on three critical elements of the global pandemic preparedness and response ecosystem—equity, financing and collaboration—were also championed by Summit participants.

?? Discover more Summit insights and recommendations

The report is available in English and Portuguese.


CEPI at UNGA 79?

Launch of CEPI Biosecurity Strategy

CEPI published its new Biosecurity Strategy at the 79th UN General Assembly last week in New York. The strategy aims to bolster global health security and underscores CEPI’s commitment to tackling emerging epidemic and pandemic threats, whether they arise naturally, accidentally or through deliberate misuse.

Developed with funding support from Global Affairs Canada | Affaires mondiales Canada , the strategy outlines how cutting-edge technologies can be harnessed and how international collaboration can be fostered to mitigate the risks posed by emerging pathogens, with a focus on biosafety and biosecurity. Its launch is a significant step in CEPI’s evolution, positioning it as a thought leader in the rapidly developing fields of biosafety and biosecurity.??

As well as embedding its biosecurity strategy into its own operations, CEPI is urging other life science research funders and the wider global health security community to recognise and address the complex challenges posed by emerging biological threats, and to work together to tackle them.

?? Learn more about CEPI’s Biosecurity Strategy

CEPI and PAHO advance regulatory harmonisation and response in the Americas

On the sidelines of UNGA 79, CEPI strengthened its collaboration with Pan American Health Organization and the Pan American Network for Drug Regulatory Harmonization (PANDRH), signing a new agreement to advance regulatory harmonisation and response to health emergencies in the Americas. Such harmonisation of regulatory processes is crucial as it fosters a common understanding among regional regulators, maximises limited regulatory resources, helps establish standards that are tailored to specific regional needs and, ultimately, can help accelerate the process of getting safe and effective diagnostics, therapeutics, and vaccines, to those who need them most.

?? Learn more


R&D and manufacturing news

SMART* trial mpox vaccination begins in the DRC ?

Co-funded by CEPI and the Canadian Institutes of Health Research | Instituts de recherche en santé du Canada , a clinical trial assessing whether mpox vaccination works after virus exposure has launched in the Democratic Republic of Congo (DRC), the country at the epicentre of a rapidly escalating outbreak of the deadly disease.

Known as the SMART* trial, the study is the first of its kind to assess whether post-exposure vaccination of Bavarian Nordic’s MVA-BN? mpox vaccine could reduce the risk of secondary mpox cases, or if it could reduce severity of illness if a person contracts the disease. Up to 1500 participants will be enrolled in the study.


The Viral Most Wanted – The Phenuiviruses

Rift Valley fever, part of the Phenuivirus family, is an acute viral haemorrhagic disease, most commonly affecting domesticated animals, like cattle, sheep, goats, and camels. It can also cause human infections and outbreaks. Symptoms are often mild, but it can progress into severe haemorrhagic disease, and in these cases, it can be fatal in up to 50% of people.

Rift Valley Fever is just one such Phenuivirus that can cause human infection…

?? Learn more about this viral family, including how its members operate, who they affect, and the lines of enquiry being pursued to help stop future outbreaks

?? Discover The Viral Most Wanted series


100 Words On… mpox

Mpox is a contagious infectious disease of the?Poxvirus family. There are two different known clades of the mpox virus: clade I and clade II. Clade I usually causes a higher percentage of infected people to get severely sick or die compared to clade II. Most people infected with mpox suffer with flu-like symptoms, as well as a skin rash featuring pus-filled lesions or blisters. An ongoing multi-country outbreak of the disease across Central and West Africa this year has led the World Health Organization and Africa CDC to declare the ongoing outbreak of mpox as both a?continental?and global health emergency.?

?? Learn more about mpox ?


???Open Calls for Proposals

?? Innovations to Prepare for Future Epidemics and Pandemics.

  • Focus Area 1: advancing innovative rapid-response vaccine platforms that can transform the response to a future Disease X.
  • Focus Area 2: developing new vaccine candidates against CEPI priority pathogens – focused on Lassa fever, Nipah, Pan-Sarbecovirus, Rift Valley fever – and viral families.


?? Reading corner


?? Tune In

From pandemic risks and climate change to nuclear war and uncontrollable AI systems, how can humanity mitigate these kinds of existential risks?

Dr Richard Hatchett—CEO of CEPI—addressed this big question in a speech at the University of Oslo earlier this month, as he accepted an?honorary doctorate.

See also Pandemic Action Network’s panel on a similar topic at UNGA 79: Pandemics, Climate, Conflict: Preventing Future Shocks

Catch up on GPPS 2024

All recordings from the Global Pandemic Preparedness Summit 2024 are now available to watch online (in English and Portuguese).

?? Watch now

?? Check out the full Summit programme here


Follow CEPI’s work

To stay up to date with CEPI’s latest announcements as they happen, follow us on social media.

Explore more at www.cepi.net

要查看或添加评论,请登录

社区洞察

其他会员也浏览了